Honestly, if you've been watching Hims & Hers Health (HIMS) lately, it feels a bit like riding a rollercoaster designed by someone who can't decide if they're building a pharmacy or a tech giant.
One day, everyone is obsessed with their GLP-1 weight loss compounding. The next, people are dumping shares because a big bank like BofA Securities decides to slash its price target. As of January 18, 2026, the vibe around the stock is... well, it's complicated.
The stock closed out last week around $31.38. That’s a far cry from its 52-week highs near $73, and honestly, it’s got a lot of retail traders wondering if the "hypergrowth" story is hitting a brick wall or just taking a very expensive breather.
What’s the deal with Hims stock news today?
The big talking point right now isn't just about how many people are buying hair loss pills. It’s about 2026 being a massive "investment year." Management basically told the street to expect a pause in margin expansion. They're pouring money into talent, tech, and their own supply chain.
For a lot of investors, "investment year" is just corporate speak for "we’re going to spend a lot of money and your earnings might look ugly for a while."
The BofA Bear Case
A few days ago, BofA Securities dropped their price target to $29.00. They're keeping an "Underperform" rating. Why? Because they think the market's expectation that Hims will add $440 million in revenue this year is, frankly, a bit too optimistic. They’re worried that the growth we saw in 2025—which was wild, by the way—is going to be hard to repeat as the competition in the weight loss space gets even more cutthroat.
👉 See also: Modern Office Furniture Design: What Most People Get Wrong About Productivity
The Bull Case (It’s still there)
But then you have firms like Leerink Partners. They actually lowered their target too—from $46 to $41—but they kept an "Outperform" rating. Their take is basically: "Yeah, they're spending money, but it’s because they’re building something huge."
They see the expansion into Canada and the new menopause and perimenopause specialties as the early stages of a $1 billion annual revenue engine for the "Hers" brand alone.
The GLP-1 Factor: Still the Elephant in the Room
You can't talk about hims stock news today without mentioning the weight loss drugs. It’s the engine that drove the stock to the moon last year.
Right now, Hims is offering compounded GLP-1s starting around $199 a month. They even launched a "microdose" version recently. It's a smart play to keep things affordable while the branded versions of Wegovy and Zepbound are still expensive or hard to find.
But there’s a massive regulatory shadow here. Back in September 2025, the FDA sent a warning letter about how Hims was marketing these compounded drugs. The agency basically said: "Hey, you can't claim these are the same as the FDA-approved branded drugs."
✨ Don't miss: US Stock Futures Now: Why the Market is Ignoring the Noise
Since then, Hims has been a lot more careful with their language, but the risk remains. If the shortage of branded semaglutide ever truly ends, the legal "loophole" that allows for large-scale compounding could tighten.
Personalization vs. Commodity
Hims is trying to move away from being a "pill mill."
About 65% of their members are now on "personalized" plans. This is huge for the business model. If you’re just buying a generic Viagra pill, you might leave for a cheaper price. If you’re on a custom-blended hair and skin regimen that’s delivered every month, you’re much "stickier."
They’re also moving into:
- Menopause care: A huge, underserved market.
- Testosterone replacement: A growing category for the "Hims" side.
- Labs and Diagnostics: They want to be the place you go to get your blood work done so they can tell you exactly what supplements or meds you need.
CEO Andrew Dudum has been very vocal about 2026 being the "Year of the Individual." He wants healthcare to feel like a consumer experience—like Netflix or Spotify—rather than a trip to a cold, sterile doctor's office.
🔗 Read more: TCPA Shadow Creek Ranch: What Homeowners and Marketers Keep Missing
Is the stock actually undervalued?
If you look at the numbers, Hims is trading at a P/E ratio of roughly 58. That sounds high until you realize they've been growing revenue at nearly 50% year-over-year.
The market cap is sitting around $7.1 billion.
- Low target: $29 (BofA)
- Average target: $44.38
- High target: $85
That’s a massive range. It tells you that even the experts don't agree on what this company is worth. Is it a pharmacy? A tech platform? A luxury brand?
Actionable Insights for Investors
If you're holding HIMS or thinking about jumping in, keep these three things in your notebook:
- Watch the February 23rd Earnings Call: This is the big one. Analysts are expecting an EPS of about $0.04. If they miss that or, more importantly, if their guidance for the rest of 2026 is weak, the stock could easily test that $25–$29 support level.
- Monitor the FDA news: Any change in the "shortage" status of semaglutide or tirzepatide is a direct threat to their weight-loss revenue. If the shortage ends, the compounding party might be over.
- The "Hers" growth rate: The company is aiming for $1 billion in revenue for the Hers brand by the end of this year. If the menopause and weight loss products for women take off, it offsets the volatility in the men's categories.
Hims is a high-beta play. It’s going to swing. But if they can actually pull off this "investment year" and come out the other side with a verticalized supply chain and a loyal, personalized subscriber base, today's $31 price point might look like a steal in 2027. Or, the spending could just eat their lunch.
Either way, it’s definitely not a boring stock to watch.
Next Steps for Your Portfolio:
- Check your exposure to the telehealth sector to ensure you aren't over-concentrated in high-growth, high-volatility names.
- Review the latest Hims & Hers Health, Inc. 10-Q filings to see the exact breakdown of their "Investment Year" capital expenditures.
- Set a price alert for $29.00, which is a key technical and psychological support level identified by several analysts this month.